Natriuretic peptides and the heart: Current and future implications for clinical biochemistry

Annals of Clinical Biochemistry

Volumn 42, Issue 6, 2005, Pages 432-440

  Penney, M D ^a  

^a ROYAL GWENT HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE HEART FAILURE; BIOCHEMISTRY; BODY POSTURE; COST EFFECTIVENESS ANALYSIS; DIETARY INTAKE; DIFFERENTIAL DIAGNOSIS; DYSPNEA; EXERCISE; GENDER; GENETICS; HEART; HEART FAILURE; HEART RATE; HUMAN; KIDNEY FAILURE; MEASUREMENT; PATHOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCREENING;

BIOLOGICAL ASSAY; FORECASTING; HEART FAILURE, CONGESTIVE; HUMANS; MASS SCREENING; NATRIURETIC PEPTIDES; PROGNOSIS; SODIUM, DIETARY;

EID: 27844446524     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/000456305774538292     Document Type: Review

References (47)

1. Petersen S, Rayner M, Wolstenholme J. Coronary Heart Disease Statistics: Heart Failure Supplement. London: British Heart Foundation, 2002
2. Leidy NK, Pentz AM, Zyczynski TM. Evaluating health-related quality-of-life outcomes in patients with congestive heart failure. A review of recent randomised controlled trials. Pharmacoeconomics 1999; 15: 19-46
3. National Institute for Clinical Excellence. Chronic heart failure: management of chronic heart failure in adults in primary and secondary care. NICE Clinical Guideline No. 5. London: National Institute for Clinical Excellence, 2003. Available from www.nice.org.uk
4. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-60
5. Houghton AR, Sparrow NJ, Toms E, Cowley AJ. Should general practitioners use the electrocardiogram to select patients with suspected heart failure for echocardiography? Int J Cardiol 1997; 62: 31-6
6. de Wardener HE, Mills IH, Clapham WF, Hayter CJ. Studies on the efferent mechanisms of the sodium diuresis which follows the administration of intravenous saline in the dog. Clin Sci 1961; 249: 249-58
7. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28: 89-94
8. Kangawa K, Matsuo H. Purification and complete amino acid sequence of α-human atrial natriuretic polypeptide (α-hANP). Biochem Biophys Res Commun 1984; 118: 131-9
9. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332: 78-81
10. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): a new member of the natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990; 168: 863-70
11. Jamison RL, Canaan-Kühl S, Pratt R. The natriuretic peptides and their receptors. Am J Kidney Dis 1992; 20: 519-30
12. Kalra PR, Clague JR, Bolger AP, et al. Myocardial production of C-type natriuretic peptide in chronic heart failure. Circulation 2003; 107: 571-3
13. Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system I: natriuretic peptides. J Hypertens 1992; 10: 907-12
14. Mair J, Hammerer-Lercher A, Puschendor JB. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001; 39: 571-88
15. Lang CC, Coutie WJ, Khong TK, Choy AMJ, Struthers AD. Dietary sodium loading increases plasma brain natriuretic peptide levels in man. J Hypertens 1991; 9: 779-82
16. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002; 40: 976-82
17. Loke I, Squire IB, Davies JE, Ng LL. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail 2003; 5: 599-606
18. Huang WS, Lee MS, Perng HW, Yang SP, Kuo SW, Chang HD. Circulating brain natriuretic peptide values in healthy men before and after exercise. Metabolism 2002; 51: 1423-6
19. Herrmann M, Scharhag J, Miclea M, Urhausen A, Herrman W, Kindermann W. Post-race kinetics of cardiac troponin T and I and N-terminal pro-brain natriuretic peptide in marathon runners. Clin Chem 2003; 49: 831-4
20. Barletta G, Stafani L, Del Bene R, et al. Effects of exercise on natriuretic peptides and cardiac function in men. Int J Cardiol 1998; 65: 217-25
21. Pedersen EB, Pedersen HB, Jensen KT. Pulsatile secretion of atrial natriuretic peptide and brain natriuretic peptide in healthy humans. Clin Sci 1999; 97: 201-6
22. Bruins S, Fokkema MR, Römer JWP, et al. High intra individual variation of B-type natriuretic peptide (BNP) and amino-terminal pro BNP in patients with stable chronic heart failure. Clin Chem 2004; 50: 2052-8
23. Wu AH, Smith A, Wieczorek S, et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003; 92: 628-31
24. Richards AM, Lainchbury JG, Nicholls MG, Troughton RW, Yandle TG. BNP in hormone-guided treatment of heart failure. Trends in Endocrin Metab 2002; 13: 151-5
25. Tabbibizar R, Maisel A. The impact of B-type natriuretic peptide levels on the diagnosis and management of congestive heart failure. Curr Opin Cardiol 2002; 17: 340-5
26. Wu AHB. B-type natriuretic peptide for congestive heart failure. J Clin Ligand Assay 2002; 2: 155-9
27. Goetze JP, Kastrup J, Pedersen F, Rehfeld JF. Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing. Clin Chem 2002; 48: 1035-42
28. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left ventricular systolic dysfunction. Lancet 1998; 351: 9-13
29. Smith H, Pickering RM, Struthers A, Simpson I, Mont D. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: observational study. Br Med J 2000; 320: 906-8
30. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1999; 350: 1349-53
31. Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J. Head to head comparison of N-terminal pro brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 2001; 310: 193-7
32. Hobbs FDR, Davis RC, Roalfe AK, Hare R, Davies MK. Reliability of N-terminal pro BNP assay in diagnosis of left ventricular systolic dysfunction within representative and high risk populations. Heart 2004; 90: 866-70
33. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Biochemical diagnosis of impaired left ventricular ejection fraction-comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and amino terminal pro BNP (NT-pro BNP). Clin Chem Lab Med 2004; 42: 159-63
34. Nielsen OW, McDonagh TA, Robb SD, Dargie HJ. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003; 41: 113-20
35. Sim V, Hampton D, Phillips C, et al. The use of brain natriuretic peptide as a screening test for left ventricular systolic dysfunction - cost-effectiveness in relation to open access echocardiography. Fam Practice 2003; 20: 570-4
36. Senior R, Galasko G, McMurray JV, Mayet J. Screening for left ventricular dysfunction in the community: role of hand held echocardiography and brain natriuretic peptides. Heart 2003; 89(Suppl III): iii24-8
37. Barth JH. Who is responsible for reference ranges? Ann Clin Biochem 2004; 41: 429
38. Dodwell C. Heart failure and brain natriuretic peptide, current evidence and issues to consider. Report for Cardiac Network Co-ordinating Group. Cardiff: National Public Health Service for Wales, 2003
39. Cowie MR. B-type natriuretic peptide testing: where are we now? Heart 2004; 90: 725-6
40. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-7
41. Meuller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnoea. N Engl J Med 2004; 350: 647-54
42. Aurigemma GP, Gaasch WH. Diastolic heart failure. N Engl J Med 2004; 351: 1097-105
43. Shapiro BP, Chen HH, Burnett JD, Redfield MM. Use of plasma brain natriuretic peptide concentration to aid the diagnosis of heart failure. Mayo Clin Proc 2003; 78: 481-6
44. Morrow DA, de Lemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol 2003; 41: 1264-72
45. Mega JL, Morrow DA, de Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004; 44: 335-9
46. Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002; 106: 2913-8
47. Craig J, Bradbury I, Cummins E, Downie S, Foster L, Stout A. The use of B-type natriuretic peptides (BNP and NT-ProBNP) in the investigation of patients with suspected heart failure. Health Technology Assessment Report 6. Scotland: NHS Quality Improvement, May 2005